Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

Maintaining Reduced Viral Fitness and CD4 Response in HIV-Infected Patients with Viremia Receiving a Boosted Protease Inhibitor

Philip Grant, Jonathan Taylor, Pat Cain, William Short, Joel Gallant, Charles Farthing, Gary Thal, Eoin Coakley and Andrew Zolopa
Clinical Infectious Diseases
Vol. 48, No. 5 (Mar. 1, 2009), pp. 680-682
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/40309284
Page Count: 3
  • Download ($42.00)
  • Subscribe ($19.50)
  • Cite this Item
Maintaining Reduced Viral Fitness and CD4 Response in HIV-Infected Patients with Viremia Receiving a Boosted Protease Inhibitor
Preview not available

Abstract

When fully suppressive regimens are not available, incompletely suppressive regimens also provide immunologic benefits. In this study, with stable background therapy, human immunodeficiency virus (HlV)-infected patients who were randomized to receive atazanavir or boosted atazanavir, compared with those who continued boosted protease inhibitor therapy, maintained similar virologic and immunologic control, resistance-mutation patterns, and replication capacities with reduced use of lipid-lowering medication.

Page Thumbnails

  • Thumbnail: Page 
680
    680
  • Thumbnail: Page 
681
    681
  • Thumbnail: Page 
682
    682